Найкращі гастроентерологи – ТОП-470 лікарів

İlknur, Karakus Şeyma, Gültekin Serap, Özçınar Beyza, Özmen Vahit, İğci Abdullah, Müslümanoğlu Mahmut Ebudeccane, Dinçcag Sait Ahmet 18-й Всесвітній конгрес SIS з охорони здоров’я молочної залози 16-19 вересня 2014 р. Орландо, США 3- Незалежне співвідношення пахвових лімфатичних вузлів Прогностичний фактор при раку молочної залози Üçüncü Muhammed Zübeyr, Karakuş Şeyma, Tükenmez Mustafa, Kaya Serdar, Yüksel Sercan, Özmen Vahit, Müslümanoğlu Mahmut Ebudeccane, Dinççağ Ahmet Sait, İğci Abdullah, Özçınar Beyza, Cabıoğlu World Health Congress1 8 вересня 16 вересня -19,2014 Орландо, США Доктор Мухаммед Зюбейр Ючюнджу є фахівцем із загальної хірургії та доцентом хірургії, має ступінь медичного факультету Стамбульського університету. Доктор Üçüncü має великий досвід лікування гострого біліарного панкреатиту, ендоскопії, травматології та невідкладної хірургії, ожиріння та здоров’я грудей. Він опублікував кілька статей у медичних журналах і виступав на міжнародних конференціях.

Prof. Carlo Castroro is the General Gastric and Esophagus Surgery Unit Director in Humanitas Research Hospital. He has graduated in the University of Padua and specialised in general medicine and thoracic surgery.

Medical areas of interest:

• gastric esophagus surgery
• day surgery
• general surgery

Previous experience:

Head of Simple Departmental Oncological Surgery Unit at the “Istituto Oncologico Veneto”, IOV - IRCCS, Padua.

Research areas of interest: 

• gastro-intestinal oncological surgery
• diseases of the esophagus with particular focus on oncologicy
• training, new technologies and distance learning
• day surgery and surgical services reorganization

Teaching experience: He is a professor in the Graduate School of General Surgery of the University of Padua and has also participated as a lecturer in numerous postgraduate training courses in the field of esophageal surgery, day surgery and minimally invasive surgery.

Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=castoro+carlo

Biography

Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:

• Oncology care and treatment for chemotherapy, hormonal therapy, immune therapy, and target therapy
• Breast cancer
• Solid tumor diagnosis
• Digestive cancer
• Gynecological cancer
• Lung cancer
• Genitourinary cancer
• Sarcoma

Awards & Achievements

• Award from Himaya Foundations and University of Sharjah

Research & Publications

• Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries' Patients: A Cross-Sectional Study of 96 Cases. Journal of Oncology Research Reviews & Reports Volume 2(2): 1-3.
• The Burden of Gynecologic Cancers in the UAE. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Before Anti-Cancer Therapy. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida , Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncology 2020 Jan;1(32):71-87.
• Primary Bone Lymphoma: Tunisian Multicentric Retrospective Study About 32 Cases. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. 2018 May;96(5):269-272.
• First Site of Recurrence After Breast Cancer Adjuvant Treatment in the Era of Multimodality Therapy: Which Imaging for Which Patient During Follow-up? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 2017 Nov 21

Prof. Alessio Michele Goffredo Aghemo is the Hepatology Unit Director in Humanitas research Hospital.

Medical areas of interest: 

• liver diseases
• viral hepatitis
• metabolic hepatitis
• liver cirrhosis

Previous experience: 

From 2007 to 2017 he was the 1st level Medical Director at the U.O of Gastroenterology of the IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan.

Research areas of interest: 

Clinical and research activity focused on natural history and treatment of viral hepatitis.

He is the author of 155 peer-reviewed publications (Impact Factor total 1151.3, H-Index 25 according to Scopus, H-Index 20 last 5 years Scopus, H-Index 30 according to Google Scholar) (updated September 2017).

From 2013 to 2016 he was a scientific member of the governing board of the European Association for the Study of the Liver (EASL).

Since 2016 he is a member of the scientific committee of the European Association of Gastroenterology (UEG).

He is a member of the AISF (Italian Association for the Study of the Liver) commission for antiviral drugs directed against HCV (2012-present). Since 2016 he has been the coordinator of the same. 

He was AIFA/EMEA expert for liver disease since 2008.

Member of the Executive Committee of the HCV Regional Network, determined by the Lombardy Region on 28 September 2015.

He participated as an expert in the drafting of the European Guidelines 2013-2014-2015-2016-2017 (EASL) and Italian (AISF) on the Treatment of Chronic Hepatitis C.

Teaching experience:

He is associated professor of Gastroenterology at Humanitas University since September 2017.

Prof. Alessandro Repici is the Director of the Gastroenterology and Digestive endoscopy Unit in Humanitas Research Hospital. Graduated in Medicine and Surgery in 1990 and the following year he won a scholarship at the Department of Gastroenterology Molinette hospital in Turin, where he began his practice in digestive endoscopy. In 1992, he worked with Prof. Claude Liguory as a fellow at the American Hospital in Paris.

In 1994 he became a specialist in Gastroenterology and Digestive Endoscopy at the University of Messina and worked in the Department of Gastroenterology, Ospedale Maggiore Molinette of Turin.

In the following years, he has been working at the Service of Digestive Endoscopy of Altona Hospital in Hamburg, directed by prof. Hagenmuller, and in the Department of Gastroenterology Molinette Hospital in Turin, directed by prof. Rizzetto. In 1999, he was a Research Fellow at the Center for Oncological and Operative Endoscopy of Wellsley Hospital in Toronto.

He teaches Gastroenterology and Digestive Endoscopy at the School of Specialization in Oncology since 2000, at the University of Turin since 2004 and Endoscopy Diagnostic Techniques and Operations at the School of Specialization in General Surgery I and II of the University of Turin.

The clinical activity and research of Prof. Repici mainly focuses on the development of new endoscopic techniques in the field of diagnosis and therapy, with particular attention to new methods of endoscopic removal of cancerous lesions and early in the palliation of advanced gastrointestinal malignancies.

Prof. Repici is coordinator, principal investigator and co-investigator in more than 50 studies, including phase II and III for FDA and EMA approval of new molecules and new instruments for diagnostic and operational endoscopy. 

Prof. Repici collaborates on research projects in the field of endoscopy with the University of Rotterdam, in Haifa, in New York and with several Italian centers. He is a member of various national and international scientific society of Gastroenterology and Digestive Endoscopy.

Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=repici+alessandro